Prognostic and predictive biomarkers. Marc Buyse International Drug Development Institute (IDDI) Louvain-la-Neuve, Belgium

Size: px
Start display at page:

Download "Prognostic and predictive biomarkers. Marc Buyse International Drug Development Institute (IDDI) Louvain-la-Neuve, Belgium"

Transcription

1 Prognostic and predictive biomarkers Marc Buyse International Drug Development Institute (IDDI) Louvain-la-Neuve, Belgium 1

2 Prognostic biomarkers (example: gene signature) 2

3 PROGNOSTIC GENE SIGNATURES Measure 25,000 genes in RNA from breast tumors Apply algorithm to identify classifier Class of good prognosis Class of poor prognosis 3

4 MAMMAPRINT Measure 25,000 genes in RNA from breast tumors Apply algorithm to identify classifier Good prognosis (no metastases at 5 years) Agendia 24,479 probe sets Poor prognosis (metastases within 5 years) Ref: van t Veer et al, Nature 2002; 415:

5 5

6 6

7 7

8 GENE SIGNATURES IN BREAST CANCER 70-gene «Amsterdam» signature (MammaPrint, Agendia) 76-gene «Rotterdam» signature (Veridex) 21-gene assay (Oncotype DX, Genomic Health) 97-gene «genomic grade» (MapQuant Dx, Ipsogen) and others These signatures were identified using different criteria and include different sets of genes. Yet they are broadly similar in their ability to classify patients to good or poor prognosis. 8

9 Ref: van de Vijver et al, NEJM 2002;347,1999

10 Impressive odds ratio: OR = (31 / 18) / (3 / 26) = 15.0 Ref: van de Vijver et al, NEJM 2002;347,1999

11 BUT poor predictive accuracy Sensitivity = 31 / 34 =.91 Specificity = 26 / 44 =.59

12 Sensitivity Even Excellent Prognostic Models may Have Poor Discriminative Power 1-Specificity Ref: Pepe, Statist Med 2005; 24:

13 Sensitivity Even Excellent Prognostic Models may Have Poor Discriminative Power Sensitivity = 91% 1-Specificity Ref: Pepe, Statist Med 2005; 24:

14 Sensitivity Even Excellent Prognostic Models may Have Poor Discriminative Power Sensitivity = 91% Specificity = 59% 1-Specificity Ref: Pepe, Statist Med 2005; 24:

15 Probability of distant metastasis at 5 years ALL SIGNATURES HAVE POOR PREDICTIVE ACCURACY Sensitivity: 52/56=93% 100% 90% 80% 70% 60% 50% 40% 30% 20% Good-Prognosis Group Poor-Prognosis Group 10% Specificity: 55/115=48% 0% Relapse Hazard Score Adapted from Foekens, Erasmus Medical Center, Rotterdam, the Netherlands

16 ALL SIGNATURES HAVE POOR PREDICTIVE ACCURACY Average risk = 7% 14% 31% < > 30 Ref: Paik et al, NEJM 2004;351,2817

17 Even Excellent Prognostic Models may Have Poor Discriminative Power Ref: Royston et al, JNCI 2008; 100:92. 17

18 Even Excellent Prognostic Models may Have Poor Discriminative Power Ref: Royston et al, JNCI 2008; 100:92. 18

19 Even Excellent Prognostic Models may Have Poor Discriminative Power 2-20 months Ref: Royston et al, JNCI 2008; 100:92. 19

20 THE YOUDEN INDEX AS A MEASURE OF PREDICTIVE ACCURACY Youden Index = Sensitivity + Specificity 1 Worst Useless * -1 0 Perfect 1 * Useless because a classification independent of true risk would classify patients equally well Ref: Youden D. Index for rating diagnostic tests. Cancer 1950; 3: 32.

21 THE YOUDEN INDEX AS A MEASURE OF PREDICTIVE ACCURACY Youden Index = Sensitivity + Specificity 1 Worst Useless * -1 0 Perfect 1 Region of interest * Useless because a classification independent of true risk would classify patients equally well Ref: Youden D. Index for rating diagnostic tests. Cancer 1950; 3: 32.

22 Sensitivity = 31 / 34 =.91 Specificity = 26 / 44 =.59 Youden Index = = 0.50

23 CLINICO-PATHOLOGICAL PROGNOSTIC FACTORS ALSO HAVE POOR PREDICTIVE ACCURACY Metastases within 5 years Sensitivity Specificity Youden Index Gene signature (Amsterdam validation) Gene signature (independent validation) Nottingham Prognostic Index Adjuvant! Online St Gallen criteria Ref: Buyse et al, JNCI 2006; 98:1183.

24 THE YOUDEN INDEX FOR EARLY BREAST CANCER PROGNOSTIC CLASSIFICATIONS Amsterdam validation Y = 0.50 Independent validation Y = 0.32 Nottingham Prognostic Index Y = 0.23 Adjuvant! Online Y = 0.16 St Gallen Y =

25 CLINICO-PATHOLOGICAL PROGNOSTIC FACTORS ALSO HAVE POOR PREDICTIVE ACCURACY Metastases within 5 years Sensitivity Specificity Youden Index Gene signature Adjuvant! Online Adjuvant! Online concordant with gene signature Adjuvant! Online discordant with gene signature Ref: Buyse et al, JNCI 2006; 98:1183.

26 THE YOUDEN INDEX FOR EARLY BREAST CANCER PROGNOSTIC CLASSIFICATIONS Adjuvant! discordant with gene signature Y = Independent validation Y = 0.32 Adjuvant! Online Y = 0.16 Adjuvant! concordant with gene signature Y =

27

28

29 IRRELEVANT SIGNATURES DISCRIMINATE HIGH AND LOW RISK PATIENTS! Ref: Venet et al, PLoS Computational Biol 2011; 7:e

30 IRRELEVANT SIGNATURES DISCRIMINATE HIGH AND LOW RISK PATIENTS! Effect of postprandial laughter on peripheral blood mononuclear cells Skin fibroblast localization Social defeat (mice brain) Ref: Venet et al, PLoS Computational Biol 2011; 7:e

31 RANDOM SIGNATURES DISCRIMINATE HIGH AND LOW RISK PATIENTS! Of 1890 signatures from the MsigDB database, 67% are associated with breast cancer outcome at P <.05 27% are associated with breast cancer outcome at P < 10-5 Cell proliferation integrates most of the prognostic information present in the breast cancer transcriptome. Ref: Venet et al, PLoS Computational Biol 2011; 7:e

32 SOME SIGNATURES REMAIN SIGNIFICANT AFTER ADJUSTMENT FOR PROLIFERATION Red squares: OS hazard ratios after adjustment for the top 1% genes more strongly correlated with proliferating cell nuclear antigen (PCNA) Ref: Venet et al, PLoS Computational Biol 2011; 7:e

33 Predictive biomarkers (example: gene mutation) 33

34 A Predictive Biomarker in NSCLC 34

35 Gefitinib vs. Chemotherapy in NSCLC Ref: Mok et al, NEJM 2009;361:947 35

36 Gefitinib vs. Chemo: EGFR Mutation Ref: Slides courtesy of Astra-Zeneca 36

37 Gefitinib vs. Chemo: No EGFR Mutation Ref: Slides courtesy of Astra-Zeneca 37

38 Gefitinib is Either Better or Worse (Qualitative Interaction) Ref: Slides courtesy of Astra-Zeneca 38

39 Validation of Predictive Biomarkers Need to show interaction between the biomarker levels at baseline, or changes of biomarker over time, and treatment effect Hence, randomized evidence is usually needed (to estimate treatment effects by biomarker levels reliably) And, interaction test has very low power 39

40 Gefitinib is Either Better or Worse (Qualitative Interaction) Treatment HR = 0.74 Interaction HR = HR(EGFR M+) / HR (EGFR M-) = 0.48 / 2.85 = 0.17 interaction effect size >> treatment effect size Interaction highly significant 40

41 Interaction Test Has a Very Low Power Inflation factor required to increase the sample size so that the interaction test has the same power as the original sample size had for the overall treatment effect. Ref: Brookes et al., J Clin Epidemiol 2004;57:229 41

42 Interaction Test Has a Very Low Power 1 Inflation factor required to increase the sample size so that the interaction test has the same power as the original sample size had for the overall treatment effect. Ref: Brookes et al.; J Clin Epidemiol 2004;57:229 42

43 Interaction Test Has a Very Low Power 4 1 Inflation factor required to increase the sample size so that the interaction test has the same power as the original sample size had for the overall treatment effect. Ref: Brookes et al.; J Clin Epidemiol 2004;57:229 43

44 Interaction Test Has a Very Low Power 0.5 Inflation factor required to increase the sample size so that the interaction test has the same power as the original sample size had for the overall treatment effect. Ref: Brookes et al.; J Clin Epidemiol 2004;57:229 44

45 Interaction Test Has a Very Low Power Inflation factor required to increase the sample size so that the interaction test has the same power as the original sample size had for the overall treatment effect. Ref: Brookes et al.; J Clin Epidemiol 2004;57:229 45

46 Validation and clinical utility Validation is relatively straightforward for prognostic biomarkers (independent of treatment) but, what is the clinical relevance? Validation is extremely challenging for predictive biomarkers (need for large randomized evidence) but clinical relevance is clear! 46

Statistical validation of biomarkers and surogate endpoints

Statistical validation of biomarkers and surogate endpoints Statistical validation of biomarkers and surogate endpoints Marc Buyse, ScD IDDI, Louvain-la-Neuve & Hasselt University, Belgium marc.buyse@iddi.com OUTLINE 1. Setting the scene: definitions and types

More information

MammaPrint, the story of the 70-gene profile

MammaPrint, the story of the 70-gene profile MammaPrint, the story of the 70-gene profile René Bernards Professor of Molecular Carcinogenesis The Netherlands Cancer Institute Amsterdam Chief Scientific Officer Agendia Amsterdam The breast cancer

More information

30 years of progress in cancer research

30 years of progress in cancer research Breast Cancer Molecular Knowledge Integrated in Clinical Practice Personalized Medicine Laura J. Esserman UCSF Comprehensive Cancer Center Retreat Breast Cancer Management Advances 80-90s 1) Screening

More information

MammaPrint Improving treatment decisions in breast cancer Support and Involvement of EU

MammaPrint Improving treatment decisions in breast cancer Support and Involvement of EU MammaPrint Improving treatment decisions in breast cancer Support and Involvement of EU 1 Bas van der Baan VP Clinical Affairs Irvine, California Amsterdam, The Netherlands 2 Two Crucial Questions in Cancer

More information

Breast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)

Breast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive

More information

ISPOR 4 th Asia Pacific Conference IP2 Gilberto de Lima Lopes

ISPOR 4 th Asia Pacific Conference IP2 Gilberto de Lima Lopes Health Economic Considerations for Personalized Medicine in Asia: Using Genomic Profiling to Guide Treatment Decisions in Early Breast Cancer Gilberto de Lima Lopes, Jr., M.D., M.B.A Assistant Director

More information

Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011

Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of

More information

The 70-Gene Signature (MammaPrint) As a Guide for the Management of Early Stage Breast Cancer. California Technology Assessment Forum

The 70-Gene Signature (MammaPrint) As a Guide for the Management of Early Stage Breast Cancer. California Technology Assessment Forum TITLE: The 70-Gene Signature (MammaPrint) As a Guide for the Management of Early Stage Breast Cancer AUTHOR: Jeffrey A. Tice, MD Assistant Professor of Medicine Division of General Internal Medicine Department

More information

Profili di espressione genica

Profili di espressione genica Profili di espressione genica Giampaolo Bianchini MD Ospedale San Raffaele, Milan - Italy Gene expression profiles Transcriptomics Gene DNA mrna mirnas Protein metilation Metabolite Genomics Transcriptomics

More information

The Current Status and the Future Prospects of Multigene testing in Europe

The Current Status and the Future Prospects of Multigene testing in Europe The Current Status and the Future Prospects of Multigene testing in Europe Emiel J. Rutgers The Netherlands Cancer Institute Antoni Van Leeuwenhoek Hospital Amsterdam St. Gallen Recommendations 2009 =

More information

Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA

Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements

More information

Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer

Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin

More information

Contemporary Classification of Breast Cancer

Contemporary Classification of Breast Cancer Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline

More information

OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER

OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER Aleix Prat, MD PhD Medical Oncology Department Hospital Clínic of Barcelona University of Barcelona esmo.org Disclosures Advisory role for

More information

Genomic platforms in breast cancer

Genomic platforms in breast cancer Genomic platforms in breast cancer Prof. Miguel Martín Instituto de Investigación Sanitaria Hospital Gregorio Marañón Universidad Complutense Madrid mmartin@geicam.org Disclosure Dr. Martin has received

More information

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular

More information

Are Genomics and proteomics biomarkers ready for prime time? National Cancer Policy Forum workshop Pierre P. Massion, MD

Are Genomics and proteomics biomarkers ready for prime time? National Cancer Policy Forum workshop Pierre P. Massion, MD Are Genomics and proteomics biomarkers ready for prime time? National Cancer Policy Forum workshop Pierre P. Massion, MD 10-05-07 Outline 1. Use of omics in patient diagnosis or stratification in cancer:

More information

Session thématisée Les Innovations diagnostiques en cancérologie

Session thématisée Les Innovations diagnostiques en cancérologie 10 èmes Journées Scientifiques du Cancéropôle Nord-Ouest 10-12 mai 2017, Deauville Session thématisée Les Innovations diagnostiques en cancérologie Les signatures multigéniques pronostiques dans le cancer

More information

Current Status and Future Development of Tools for Prognosis and Prediction - USA

Current Status and Future Development of Tools for Prognosis and Prediction - USA Current Status and Future Development of Tools for Prognosis and Prediction - USA John H. Ward, MD Professor of Medicine University of Utah School of Medicine Huntsman Cancer Institute October18, 2009

More information

n. 5 TECHNOLOGY COMMERCIAL TECHNOLOGY PRODUCER / SUPPLIER USE CATEGORY THERAPEUTIC OR DIAGNOSTIC FIELD OF APPLICATION PATIENTS / CLINICAL CONDITION

n. 5 TECHNOLOGY COMMERCIAL TECHNOLOGY PRODUCER / SUPPLIER USE CATEGORY THERAPEUTIC OR DIAGNOSTIC FIELD OF APPLICATION PATIENTS / CLINICAL CONDITION TECHNOLOGY In vitro test, based on a microarray methodology, that measures the level of activity of genes in a sample of surgically removed breast of women treated for breast cancer. The test is used to

More information

Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint

Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical

More information

Adjuvan Chemotherapy in Breast Cancer

Adjuvan Chemotherapy in Breast Cancer Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality

More information

Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE. August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario

Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE. August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario Session: Correlative Studies in Phase III Trials Title: Design

More information

Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón

Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón Universidad Complutense Madrid The new technologies

More information

Luminal A and B Where are we? (or lost in translation?)

Luminal A and B Where are we? (or lost in translation?) Luminal A and B Where are we? (or lost in translation?) Emiel J. Rutgers The Netherlands Cancer Institute Antoni Van Leeuwenhoek Hospital Amsterdam How to determine adjuvant or neoadjuvant treatment for

More information

Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI

Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo BREAST CANCER Brain Adjuvant Medical Therapies

More information

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The National Surgical

More information

A breast cancer gene signature for indolent disease

A breast cancer gene signature for indolent disease Breast Cancer Res Treat (2017) 164:461 466 DOI 10.1007/s10549-017-4262-0 EPIDEMIOLOGY A breast cancer gene signature for indolent disease Leonie J. M. J. Delahaye 1 Caroline A. Drukker 2,3 Christa Dreezen

More information

Gene-Expression Profiling and the Future of Adjuvant Therapy

Gene-Expression Profiling and the Future of Adjuvant Therapy Gene-Expression Profiling and the Future of Adjuvant Therapy Marc van de Vijver Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands Key Words. Gene-expression profiling Prognostic

More information

New Developments in Cancer Treatment. Ian Rabinowitz MD

New Developments in Cancer Treatment. Ian Rabinowitz MD New Developments in Cancer Treatment Ian Rabinowitz MD Treatment Outline Angiogenesis inhibition Targeted therapy Immunotherapy Personalization of therapy Genomics and cancer Stem cells and cancer Angiogenesis

More information

8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview

8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay

More information

Breast Cancer: Who Gets It? Who Survives? The Latest Information

Breast Cancer: Who Gets It? Who Survives? The Latest Information Breast Cancer: Who Gets It? Who Survives? The Latest Information James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine

More information

Molecular Characterization of Breast Cancer: The Clinical Significance

Molecular Characterization of Breast Cancer: The Clinical Significance Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville

More information

Adjuvant endocrine therapy (essentials in ER positive early breast cancer)

Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine

More information

Predictive Assays in Radiation Therapy

Predictive Assays in Radiation Therapy Outline Predictive Assays in Radiation Therapy Radiation Biology Introduction Early predictive assays Recent trends in predictive assays Examples for specific tumors Summary Lecture 4-23-2014 Introduction

More information

Personalized Treatment Breast Cancer MammaPrint Science to Healthcare

Personalized Treatment Breast Cancer MammaPrint Science to Healthcare Personalized Treatment Breast Cancer MammaPrint Science to Healthcare Laura J. van t Veer University of California, San Francisco & Agendia, Amsterdam/Irvine EC conference - 2019 Integrating Genomics into

More information

MEDICAL POLICY. SUBJECT: GENETIC ASSAY OF TUMOR TISSUE TO DETERMINE PROGNOSIS OF BREAST CANCER (OncotypeDX TM, MammaPrint )

MEDICAL POLICY. SUBJECT: GENETIC ASSAY OF TUMOR TISSUE TO DETERMINE PROGNOSIS OF BREAST CANCER (OncotypeDX TM, MammaPrint ) MEDICAL POLICY PAGE: 1 OF: 8 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.

More information

Gene Expression Profiling for Managing Breast Cancer Treatment. Policy Specific Section: Medical Necessity and Investigational / Experimental

Gene Expression Profiling for Managing Breast Cancer Treatment. Policy Specific Section: Medical Necessity and Investigational / Experimental Medical Policy Gene Expression Profiling for Managing Breast Cancer Treatment Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:

More information

Making Understanding Molecular Profiles Less Painful. Presenter Disclosure Information

Making Understanding Molecular Profiles Less Painful. Presenter Disclosure Information Welcome to Master Class for Oncologists Miami, FL December 18, 2009 Session 1: 1:00 PM - 1:45 PM Towards Personalized Medicine in Breast Cancer: Understanding Molecular Subtypes and the Role of Diagnostics

More information

Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?

Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London

More information

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work.

Protocol. This trial protocol has been provided by the authors to give readers additional information about their work. Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Cardoso F, van t Veer LJ, Bogaerts J, et al. 70-Gene signature as an

More information

Reliable Evaluation of Prognostic & Predictive Genomic Tests

Reliable Evaluation of Prognostic & Predictive Genomic Tests Reliable Evaluation of Prognostic & Predictive Genomic Tests Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov Different Kinds of Biomarkers Prognostic

More information

Type: Evidence Based Evidence Quality: High Strength of Recommendation: Strong

Type: Evidence Based Evidence Quality: High Strength of Recommendation: Strong Clinical Question 1: For women with early-stage invasive breast cancer and with known estrogen and progesterone receptor (ER/PgR) and human epidermal growth factor receptor 2 (HER2 status), which other

More information

UvA-DARE (Digital Academic Repository) Prognostic factors in breast cancer: one fits all? Mook, S. Link to publication

UvA-DARE (Digital Academic Repository) Prognostic factors in breast cancer: one fits all? Mook, S. Link to publication UvA-DARE (Digital Academic Repository) Prognostic factors in breast cancer: one fits all? Mook, S. Link to publication Citation for published version (APA): Mook, S. (2011). Prognostic factors in breast

More information

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors

More information

National Medical Policy

National Medical Policy National Medical Policy Subject: Policy Number: MammaPrint, Prosigna and Other Gene Expression Tests for Breast Cancer NMP520 Effective Date*: May 2013 Updated: June 2017 This National Medical Policy is

More information

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin

UK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University

More information

Genomic Profiling in Early Stage Breast Cancer. James V. Pellicane, MD, FACS Director of Breast Oncology Bon Secours Cancer Institute Richmond, VA

Genomic Profiling in Early Stage Breast Cancer. James V. Pellicane, MD, FACS Director of Breast Oncology Bon Secours Cancer Institute Richmond, VA Genomic Profiling in Early Stage Breast Cancer James V. Pellicane, MD, FACS Director of Breast Oncology Bon Secours Cancer Institute Richmond, VA 1 Disclosures Speakers Bureau Agendia Focal Therapeutics

More information

Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President

Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President Symposium «Evaluation of the Belgian Cancer Plan» Brussels, November 26th, 2012 Personalized oncology in Europe: only a dream if national health systems do not get involved in diagnostics and pivotal cancer

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides

More information

Personalized Therapy for Prostate Cancer due to Genetic Testings

Personalized Therapy for Prostate Cancer due to Genetic Testings Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center

More information

Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10).

Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10). Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10). Erratum to the EAG Diagnostic Assessment Report Produced by: Sheffield University School of

More information

Breast cancer classification: beyond the intrinsic molecular subtypes

Breast cancer classification: beyond the intrinsic molecular subtypes Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification

More information

III Congreso Internacional de Oncologia del Interior XII Jornadas de Oncologia del Interior Cordoba Argentina. Farmacogenomica y Cancer de Mama

III Congreso Internacional de Oncologia del Interior XII Jornadas de Oncologia del Interior Cordoba Argentina. Farmacogenomica y Cancer de Mama III Congreso Internacional de Oncologia del Interior XII Jornadas de Oncologia del Interior Cordoba Argentina Farmacogenomica y Cancer de Mama Vicente Valero, M.D., F.A.C.P. Professor of Medicine Deputy

More information

Mechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center

Mechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal

More information

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer:

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: EAG Addendum to responses to Comments on DCD2 (5 June 2018) This document provides the EAG s responses to key themes

More information

Breast Cancer Heterogeneity

Breast Cancer Heterogeneity Breast Cancer Heterogeneity Session 2: 8:15 AM 9:00 AM Molecular Subsets and Molecular Diagnostics in Breast Cancer ER + subtypes ER-negative subtypes Lisa A. Carey, MD University of North Carolina Lineberger

More information

DIAGNOSTICS ASSESSMENT PROGRAMME

DIAGNOSTICS ASSESSMENT PROGRAMME DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10) This overview summarises the key issues

More information

Classification of cancer profiles. ABDBM Ron Shamir

Classification of cancer profiles. ABDBM Ron Shamir Classification of cancer profiles 1 Background: Cancer Classification Cancer classification is central to cancer treatment; Traditional cancer classification methods: location; morphology, cytogenesis;

More information

Search for Randox, Blueprint, PAM50, Breast Cancer Index, IHC4, Mammostrat, and NPI+ Date limits = 2002 date Filter = human studies only

Search for Randox, Blueprint, PAM50, Breast Cancer Index, IHC4, Mammostrat, and NPI+ Date limits = 2002 date Filter = human studies only Appendix 1 Search strategy Update search for Oncotype DX, and MammaPrint Date limits = January 2009 date Filter = human studies only 1. exp Breast Neoplasms/ 2. exp mammary neoplasms/ 3. exp "Neoplasms,

More information

Bridging Genomics and Therapy Creating a Theranostics Paradigm

Bridging Genomics and Therapy Creating a Theranostics Paradigm Bridging Genomics and Therapy Creating a Theranostics Paradigm Samuel Abraham, PhD VP Strategic Relationships BC Cancer Agency Diponkar Banerjee MBChB, PhD, FRCPC Executive Medical Director PHSA Laboratories

More information

Big data vs. the individual liver from a regulatory perspective

Big data vs. the individual liver from a regulatory perspective Big data vs. the individual liver from a regulatory perspective Robert Schuck, Pharm.D., Ph.D. Genomics and Targeted Therapy Office of Clinical Pharmacology Center for Drug Evaluation and Research Food

More information

The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer

The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate

More information

Rationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York

Rationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Rationale For & Design of TAILORx Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Declining Breast Cancer Mortality & Event Rates in Adjuvant

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Assays of Genetic Expression in Tumor Tissue as a Technique Page 1 of 47 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Assays of Genetic Expression in Tumor Tissue

More information

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue. Innovation for your breast cancer diagnostics PGR G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C G AT C G A A A G A A G T TA G ATA G C G A C ERBB2

More information

SPECIAL PLENARY SESSION: Results of MINDACT clinical trial

SPECIAL PLENARY SESSION: Results of MINDACT clinical trial SPECIAL PLENARY SESSION: Results of MINDACT clinical trial S Delaloge, Gustave Roussy On behalf of the European Commissionsupported TRANSBIG consortium and MINDACT investigators - 10041-3-04 «Microarray

More information

Heather Wakelee, M.D.

Heather Wakelee, M.D. Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.

More information

Learning Objectives. Financial Disclosure. Breast Cancer Quality Improvement Project with Oncotype DX. Nothing to disclose

Learning Objectives. Financial Disclosure. Breast Cancer Quality Improvement Project with Oncotype DX. Nothing to disclose Breast Cancer Quality Improvement Project with Oncotype DX Denise Johnson Miller, MD, FACS Medical Director Breast Surgery Hackensack Meridian Health Legacy Meridian (Jersey Shore University Medical Center,

More information

Harmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY

Harmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY Harmesh Naik, MD. Hope Cancer Clinic PERSONALIZED CANCER TREATMENT USING LATEST IN MOLECULAR BIOLOGY A NEW GENE A DAY.WHILE YOU ARE ENJOYING MORNING COFFEE From cancer.gov GOALS FOR THE CME TODAY A brief

More information

Modern classification of breast cancer-should we stick with morphology or convert to molecular profiles?

Modern classification of breast cancer-should we stick with morphology or convert to molecular profiles? Modern classification of breast cancer-should we stick with morphology or convert to molecular profiles? Ian Ellis Professor of Cancer Pathology Molecular Medical Sciences University of Nottingham Dept

More information

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue.

Molecular in vitro diagnostic test for the quantitative detection of the mrna expression of ERBB2, ESR1, PGR and MKI67 in breast cancer tissue. Innovation for your breast cancer diagnostics Now valid ated on: -Roche cob as z 480 A nalyzer -Roche L ightcycle r 480 II - ABI 750 0 Fast -Versant kpcr Cyc ler PGR ESR1 MKI67 Molecular in vitro diagnostic

More information

Research Article Breast Cancer Prognosis Risk Estimation Using Integrated Gene Expression and Clinical Data

Research Article Breast Cancer Prognosis Risk Estimation Using Integrated Gene Expression and Clinical Data BioMed Research International, Article ID 459203, 15 pages http://dx.doi.org/10.1155/2014/459203 Research Article Breast Cancer Prognosis Risk Estimation Using Integrated Gene Expression and Clinical Data

More information

Seigo Nakamura,M.D.,Ph.D.

Seigo Nakamura,M.D.,Ph.D. Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth

More information

1 INTRODUCTION REVIEW ARTICLE

1 INTRODUCTION REVIEW ARTICLE Received: 12 December 2016 Revised: 15 December 2016 Accepted: 15 December 2016 DOI 10.1002/jso.24561 REVIEW ARTICLE Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical

More information

The Ideal Evaluation of a Risk Prediction Model: A Randomized Clinical Trial

The Ideal Evaluation of a Risk Prediction Model: A Randomized Clinical Trial 1/25 The Ideal Evaluation of a Risk Prediction Model: A Randomized Clinical Trial Holly Janes Fred Hutchinson Cancer Research Center 2/25 Context Often a risk prediction model is developed to identify

More information

The Oncotype DX Assay A Genomic Approach to Breast Cancer

The Oncotype DX Assay A Genomic Approach to Breast Cancer The Oncotype DX Assay A Genomic Approach to Breast Cancer Pathology: 20 th and 21 st Century Size Age Phenotype Nodal status Protein/Gene Genomic Profiling Prognostic & Predictive Markers Used in Breast

More information

Concordance among Gene-Expression Based Predictors for Breast Cancer

Concordance among Gene-Expression Based Predictors for Breast Cancer The new england journal of medicine original article Concordance among Gene-Expression Based Predictors for Breast Cancer Cheng Fan, M.S., Daniel S. Oh, Ph.D., Lodewyk Wessels, Ph.D., Britta Weigelt, Ph.D.,

More information

Integrating biomarkers in clinical trials

Integrating biomarkers in clinical trials ert Review of Molecular Diagnostics ISSN: 1473-7159 (Print) 1744-8352 (Online) Journal homepage: http://www.tandfonline.com/loi/iero20 Integrating biomarkers in clinical trials Marc Buyse, Stefan Michiels,

More information

38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %

38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI % 38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype

More information

Integrative analysis of survival-associated gene sets in breast cancer

Integrative analysis of survival-associated gene sets in breast cancer Varn et al. BMC Medical Genomics (2015) 8:11 DOI 10.1186/s12920-015-0086-0 RESEARCH ARTICLE Open Access Integrative analysis of survival-associated gene sets in breast cancer Frederick S Varn 1, Matthew

More information

Overview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade

Overview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade Overview of Biomarker Development for Immune PD-1/L1 Checkpoint Blockade David L. Rimm MD-PhD Professor Departments of Pathology and Medicine (Oncology) Director, Yale Pathology Tissue Services Disclosures

More information

Input from patient representatives, external expert and manufacturer on the 2nd draft assessment MammaPrint - Added value of using gene-expression

Input from patient representatives, external expert and manufacturer on the 2nd draft assessment MammaPrint - Added value of using gene-expression Input from patient representatives, external expert and manufacturer on the 2nd draft assessment MammaPrint - Added value of using gene-expression signature for adjuvant chemotherapy decisions in early

More information

Cancer Biomarkers, Clinical Trials, and New Treatment Options. Joseph A. Sparano, MD

Cancer Biomarkers, Clinical Trials, and New Treatment Options. Joseph A. Sparano, MD Cancer Biomarkers, Clinical Trials, and New Treatment Options Joseph A. Sparano, MD Professor of Medicine & Women s s Health Albert Einstein College of Medicine Associate Chairman, Dept. of Medical Oncology

More information

upa: From Pilot Studies to Recommendation for Clinical Use Professor Joe Duffy St Vincent s University Hospital,

upa: From Pilot Studies to Recommendation for Clinical Use Professor Joe Duffy St Vincent s University Hospital, upa: From Pilot Studies to Recommendation for Clinical Use Professor Joe Duffy St Vincent s University Hospital, Dublin and University College Dublin Most Important t Questions After a Diagnosis of Breast

More information

Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives

Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast

More information

Linking Tissue Microarchitectures to Rationalized Molecular Diagnostics in Glandular Cancers

Linking Tissue Microarchitectures to Rationalized Molecular Diagnostics in Glandular Cancers Linking Tissue Microarchitectures to Rationalized Molecular Diagnostics in Glandular Cancers Kelvin K. Tsai, M.D., Ph.D. Laboratory for Tumor Epigenetics and Stemness (TES Lab) NATIONAL INSTITUTE OF CANCER

More information

She counts on your breast cancer expertise at the most vulnerable time of her life.

She counts on your breast cancer expertise at the most vulnerable time of her life. HOME She counts on your breast cancer expertise at the most vulnerable time of her life. Empowering the right treatment choice for better patient outcomes. The comprehensive genomic assay experts trust.

More information

Immunohistochemical classification of breast tumours

Immunohistochemical classification of breast tumours Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,

More information

Gene signature for risk stratification and treatment of breast cancer: Incorporating tumor biology in clinical decision-making Drukker, Caroline

Gene signature for risk stratification and treatment of breast cancer: Incorporating tumor biology in clinical decision-making Drukker, Caroline UvA-DARE (Digital Academic Repository) Gene signature for risk stratification and treatment of breast cancer: Incorporating tumor biology in clinical decision-making Drukker, Caroline Link to publication

More information

Breast Cancer Assays of Genetic Expression in Tumor Tissue

Breast Cancer Assays of Genetic Expression in Tumor Tissue Breast Cancer Assays of Genetic Expression in Tumor Tissue Policy Number: Original Effective Date: MM.12.009 12/02/2008 Line(s) of Business: Current Effective Date Section: 05/25/2018 Other Miscellaneous

More information

Oncotype DX MM /01/2008. HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office

Oncotype DX MM /01/2008. HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office Oncotype DX Policy Number: Original Effective Date: MM.12.009 12/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office

More information

micrornas (mirna) and Biomarkers

micrornas (mirna) and Biomarkers micrornas (mirna) and Biomarkers Small RNAs Make Big Splash mirnas & Genome Function Biomarkers in Cancer Future Prospects Javed Khan M.D. National Cancer Institute EORTC-NCI-ASCO November 2007 The Human

More information

Combinatorial biomarker expression in breast cancer

Combinatorial biomarker expression in breast cancer Combinatorial biomarker expression in breast cancer Emad A. Rakha, Jorge S. Reis-Filho, Ian O. Ellis To cite this version: Emad A. Rakha, Jorge S. Reis-Filho, Ian O. Ellis. Combinatorial biomarker expression

More information

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk

Tamoxifen therapy benefit for patients with 70-gene signature high and low risk Breast Cancer Res Treat (2017) 166:593 601 DOI 10.1007/s10549-017-4428-9 EPIDEMIOLOGY Tamoxifen therapy benefit for patients with 70-gene signature high and low risk Laura J. van t Veer 1 Christina Yau

More information

Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression

Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Claudin-4 Expression in Triple Negative Breast Cancer: Correlation with Androgen Receptors and Ki-67 Expression Mona A. Abd-Elazeem, Marwa A. Abd- Elazeem Pathology department, Faculty of Medicine, Tanta

More information

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT

More information

OUTLINE PAST PRESENTFUTURE BREAST CANCER INCIDENCE AND MORTALITY CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM

OUTLINE PAST PRESENTFUTURE BREAST CANCER INCIDENCE AND MORTALITY CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM OUTLINE CURRENT STATE OF MEDICAL ONCOLOGY SECOND ANNUAL BREAST CANCER SYMPOSIUM October 11, 2014 SARA M GARRIDO, M.D., F.A.C.P Chief Medical Officer at AMS Miami, October 11, 2014 PAST PRESENTFUTURE -BRIEF

More information